CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Bristol-Myers Squibb Company (BMY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Bristol-Myers Squibb Company (BMY)

Pharmaceutical Preparations · market cap $126.6B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Bristol Myers Squibb (BMY) is a Princeton, NJ-based large-cap pharma (~$125.9B market cap, ~32,500 employees) that generated $48.2B of revenue and $7.05B of net income in 2025. Eliquis (30% of 2025 revenue), Opdivo (21%), Orencia (8%) and Revlimid (6%) account for roughly 65% of sales. The setup is a broad Phase 2/3 pipeline, with a dense catalyst run starting with earnings on 2026-10-29 and an estimated KarXT Phase 3 readout around 2026-11-01.
The catalyst path
  • 2026-12-15 (est.)Phase 2 · Elotuzumabimp 7/10
  • 2026-12-20 (est.)Phase 2 · Nivolumabimp 7/10
  • 2026-12-30 (est.)Phase 2 · Ipilimumabimp 7/10
  • 2026-12-31 (est.)Phase 3imp 7/10
  • 2026-12-31 (est.)Phase 2 · Nivolumab inimp 7/10
  • 2027-01-01Otherimp 4/10
  • 2027-01-15 (est.)Phase 2 · Nivolumabimp 7/10
  • 2027-02-05 (est.)Phase 2 · Nivolumabimp 7/10
Pipeline
AssetPhaseIndication
Arlocabtagene AutoleucelPhase 2Multiple Myeloma
CC-97540Phase 2Lupus Erythematosus, Systemic
MDX-010/MDX-010 + DocetaxelPhase 2Prostate Cancer
Drugs NivolumabPhase 2Renal Cell Carcinoma, Clear Cell
BMS-986213 (Relatlimab-Nivolumab FDC)Phase 2Renal Cell Carcinoma, Clear Cell
Nivolumab, Surgery, RadiotherapyPhase 2Squamous Cell Carcinoma of the Oral Cavity
SOXPhase 2Gastric Cancer
Relatlimab + NivolumabPhase 2Melanoma
VinfluninePhase 3Bladder Cancer
Nivolumab, Surgery, ChemoradiotherapyPhase 2Squamous Cell Carcinoma of the Oral Cavity
cabiralizumabPhase 2Peripheral T Cell Lymphoma
BMS-650032 (NS3 Protease Inhibitor)Phase 2Hepatitis C
Belatacept More Intensive Regimen (MI)Phase 3Renal Transplantation
Belatacept Less Intensive Regimen (LI)Phase 3Renal Transplantation
Combination of varlilumab and nivolumabPhase 2Squamous Cell Carcinoma of the Head and Neck (SCCHN)
MDX-1379 (gp100) Melanoma Peptide VaccinePhase 3Melanoma
Nivolumab & IpilimumabPhase 2Prostate Cancer
GalunisertibPhase 2Solid Tumor
Pegylated Interferon Lambda (pegIFNλ)Phase 2Hepatitis C
PegIFN lambdaPhase 2Hepatitis B Virus
Price & technical context
3-month
-4.5%
6-month
+10.1%
12-month
+29.7%
52-wk range
$45.79–$68.09
vs 50-day MA
+2.0%
vs 200-day MA
+4.5%
Realized vol
27.4%
Max drawdown
-32.5%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for BMY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.